QSAM Biosciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Douglas R. Baum
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Plaza 1 Austin TX United States of America 78759
- IPO Date
- Aug 13, 2012
- CIK
- 0001310527
- Website
- qsambio.com
- Similar Companies
- Business
- QSAM Biosciences, Inc. (Ticker: QSAM) develops and commercializes innovative radiopharmaceuticals for the treatment of cancer patients. The company offers a portfolio of targeted alpha therapies, including lead candidate 177Lu-DOTATATE for neuroendocrine tumors and 225Ac-DOTATATE for advanced applications; imaging agents such as 68Ga-DOTATATE for diagnostic purposes; and investigational products like QSAM-288 for prostate cancer and other solid tumors. These products leverage alpha-emitting isotopes for precision oncology, providing therapeutic and diagnostic solutions across various cancer types. Headquartered in Chicago, Illinois, and founded in 2013, QSAM operates primarily in the United States with research and clinical development activities extending to select international sites for trials and partnerships. The company serves oncologists, nuclear medicine specialists, and healthcare providers targeting patients with hard-to-treat cancers, operating within the radiopharmaceutical and precision medicine segments of the biotechnology industry.
QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023
QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
QSAM Biosciences Receives Patents in Japan and Canada; Strengthens Licensed IP Portfolio in Key Markets
QSAM Biosciences Issues Letter from CEO on Successful Achievements and Future Milestones for Company
QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
QSAM Biosciences Clarifies Recent Promotional and Trading Activities at the Request of OTC Markets